Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus

Journal of Hypertension

Volumn 23, Issue 2, 2005, Pages 435-444

  Rosei, Enrico Agabiti ^a   Rizzoni, Damiano ^a   Muiesan, Maria Lorenza ^a   Sleiman, Intissar ^a   Salvetti, Massimo ^a   Monteduro, Cristina ^a   Porteri, Enzo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Adhesion molecules; Blood pressure; Candesartan; Clinical trials; Diabetes mellitus; Enalapril; Hypertension

Indexed keywords

BIOCHEMICAL MARKER; BLOOD CLOTTING FACTOR; CANDESARTAN HEXETIL; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; SEROTONIN ANTAGONIST; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL WALL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINARY EXCRETION; VASCULAR ENDOTHELIUM;

EID: 14044250200     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200502000-00027     Document Type: Article

References (39)

1. Luscher TF, Noll G. Endothelial function as an end-point in interventional trials: concepts, methods and current data. J Hypertens 1996; 14(Suppl 2):S111-S121.
2. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Valentini U, Cimino A, et al. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non insulin dependent diabetes mellitus. Circulation 2001; 103:1238-1244.
3. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994; 343:831-836.
4. Bevilacqua MP. Endothelial-leucocyte adhesion molecules. Annu Rev Immunol 1993; 11:767-804.
5. Cheng JJ, Wung BS, Chao YJ, Wang DL. Cyclic strain enhances adhesion of monocytes to endothelial cells by increasing intercellular adhesion molecule-1 expression. Hypertension 1996; 28:386-391.
6. DeSouza CA, Dengel DR, Macko FR, Cox K, Seals DR. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10:1335-1341.
7. Gasic S, Wagner OF, Fasching P, Ludwig C, Veitl M, Kapiotis S, Jilma B. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am J Hypertens 1999; 12:217-222.
8. Steiner M, Reinhardt KM, Krammer B. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost 1994; 72:979-984.
9. Wagner OF, Jilma B. Putative role of adhesion molecules in metabolic disorders. Horm Metab Res 1997; 29:1-4.
10. Ferri C, Desideri G, Baldoncini R, Bellini C, Angelis C, De Mazzocchi C, Santucci A. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities. Diabetes 1998; 47:660-667.
11. Rizzoni D, Porteri E, Guelfi D, Muiesan ML, Piccoli A, Valentini U, et al. Endothelial dysfunction in small resistance arteries of patients with non-insulin dependent diabetes mellitus. J Hypertens 2001; 19:913-919.
12. Lip GY, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implication for atherogenesis? A preliminary report. J Hypertens 1995; 13:1674-1678.
13. Cheng JJ, Wung BS, Chao YJ, Wang DL. Cyclic strain enhances adhesion of monocytes to endothelial cells by increasing intracellular adhesion molecule-I expression. Hypertension 1996; 28:386-391.
14. De Caterina R, Basta G, Lazzerini G, Dell Olmo G, Petrucci R, Morale M, et al. Soluble vascular cell adhesion molecule-I as a biohumoral correlate of atherosclerosis. Atheroscler Thromb Vasc Biol 1997; 17:2646-2654.
15. Winkelmann BR, Nauck M, Hoffmann M, Matheis G, Senges J, Marz W. Baseline levels of cell adhesion molecules P-selectin and ICAM-1 predicts 5 year survival in patients with coronary artery disease. Abstracts from the 48th Annual Scientific Sessions American College of Cardiology. New Orleans, 7-10 Marzo 1999. J Am Coll Cardiol 1999; 33:300A.
16. Wallen NH. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. Eur Heart J 1999; 20:1039-1043.
17. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J, for the StheroGene Investigators. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104:1336-1342.
18. Hwang S, Ballantyne CM, Sharret AR, Smith LC, Davis CE, Gotto AM, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary artery disease cases: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96:4215-4219.
19. Ridker P, Hennekens CH, Rottman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule-1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 251:88-92.
20. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334:939-945.
21. Ruggenenti P, Remuzzi G. Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease. Curr Opin Nephrol Hypertens 1997; 6:489-495.
22. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346:1145-1151.
23. Bonow RO, Mitch WE, Nesto RW, O'Gara P, Becker RC, Clark LT, et al. Prevention Conference VI. Diabetes and cardiovascular disease. Writing Group VI: Management of cardiovascular-renal complications. Circulation 2002; 105:e159-e164.
24. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effects of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
25. Lewis EJ, Hunsicker LG, Clarke WR. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
26. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
27. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell Olmo G, Catapano G, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344:549-550.
28. Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudani I, Arrighi P, Salvetti A. Lack of correlation between microalbuminuria and endothelial function in essential hypertensive patients. J Hypertens 1995; 13:1003-1008.
29. Rizzoni D, Muiesan ML, Porteri E, Castellano M, Salvetti M, Monteduro C, et al. Circulating adhesion molecules and carotid artery structural changes in patients with noninsulin-dependent diabetes mellitus. J Hum Hypertens 2003; 17:463-470.
30. Guidelines Subcommittee. World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension 1999. J Hypertens 1999; 17:151-183.
31. O'Brian E, Waeber B, Parati G, Staessen J, Myers MG. on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. Blood pressure monitoring devices: recommendations of the European Society of Hypertension. BMJ 2003; 322:531-536.
32. Hlubocka Z, Umnerova V, Heller S, Peleska J, Jindra A, Jachymova M, et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J Hum Hypertens 2002; 16:557-562.
33. Blann AD, Tse W, Maxwell SJ, Waite MA. Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J Hypertens 1994; 12:925-928.
34. Stehouwer CD, Fischer HR, van Kuijk AW, Polak BC, Donker AJ. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 1995; 44:431-436.
35. Ferri C, Bellini C, Desideri G, De Mattia G, Santucci A. Endogenous insulin modulates circulating endothelin-1 concentrations in humans. Diabetes Care 1996; 19:504-506.
36. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type-1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89:6998-7002.
37. Rosenson RS, Koenig W. High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. Curr Opin Cardiol 2002; 17:325-331.
38. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon 3rd RO, Criqui M, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
39. Cottone S, Mule G, Amato F, Riccobene R, Vadala A, Lorito MC, et al. Amplified biochemical activation of endothelial function in hypertension associated with moderate to severe renal failure. J Nephrol 2002; 15:643-648.